Ocugen Q3 net loss $0.06/sh; OCU400 shows 83% stabilization rate; OCU500 selected by NIH

Ocugen, Inc.

2023-Q3 EPS reported -$0.22 revenue$4,627,000

Q3 2023 net loss $0.06 per share vs $0.10 year ago; cash $53.5M, down from $90.9M at Dec 2022.
OCU400 Phase 1/2: 83% (10/12) subjects stabilized/improved in BCVA, LLVA, or MLMT; 86% (6/7) RHO subjects improved MLMT.
Completed dosing three LCA patients including pediatric; Phase 3 for RP expected early 2024.
OCU500 (mucosal COVID vaccine) selected by NIH/NIAID Project NextGen for clinical trial inclusion.
OpEx $15.4M in Q3 2023 vs $23.1M in Q3 2022; R&D $6.3M, G&A $9.1M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ocugen, Inc. reported third quarter 2023 results: EPS $0.06 net loss per common share.

Period: third quarter 2023
EPS: $0.06 net loss per common share
Result: reported results

Exact text from the filing

Ocugen reported a $0.06 net loss per common share for the three months ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-038028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.